Ticagrelor vs Clopidogrel in low risk coronary syndrome

Original Title: Effects of Ticagrelor versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI. Reference: Dominick J et al. J Am Coll Cardiol. 2016;67(6):603-613.

 

Many patients admitted with low-risk acute coronary syndrome (ACS) are not pre-treated with a P2Y12 receptor inhibitors despite the invasive strategy in place, with angiography and PCI in the same procedure.

No studies assess the pharmacodynamics of ticagrelor vs clopidogrel in “ad hoc” PCI.

The aim of this study was to assess the pharmacodynamics of ticagrelor versus clopidogrel loading dose (LD) in the peri-procedural period among troponin-negative ACS patients undergoing angiography and PCI in the same procedure.

This was a prospective, open and multicenter study in phase IV, where 100 P2Y12 inhibitor naive patients admitted with ACS with negative biomarkers were randomized to 180 mg ticagrelor loading dose vs. 600 mg of clopidogrel loading dose.

Platelet reactivity was measured at baseline, 30 minutes, 2 hours and 8 hours after loading dose and at the end of PCI, with the VerifyNow system. Primary end point was platelet reactivity at 2 hours after loading dose measured in P2Y12 reaction units (PRU); there was also an exploratory analysis on high reactivity rates (PRU >208).

At 2 hours, PRU level was significantly lower in those receiving ticagrelor vs. clopidogrel (98.4 ± 95.4 vs. 257.5 ± 74.5; p < 0.001). PRU levels started to separate at 30 minutes with the most significant difference observed at the end of PCI, and maintained up to 8 hours after loading dose. High platelet reactivity rates also saw a reduction with ticagrelor.

Conclusion
In patients undergoing low risk acute coronary syndrome undergoing ad hoc PCI, ticagrelor offers faster and more powerful platelet inhibition compared to clopidogrel.

More articles by this author

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...